Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Procedure;

Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation

By Product Type;

Mechanical Heart Valves, Tissue Heart Valves, and Transcatheter Heart Valves

By Application;

Hospitals, Cardiac Catheterization Laboratory, Ambulatory Surgical Centers (ASCs), and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn465684497 Published Date: May, 2025 Updated Date: June, 2025

Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Overview

Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market (USD Million)

Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market was valued at USD 7,382.81 million in the year 2024. The size of this market is expected to increase to USD 19,842.55 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 15.2%.


Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 15.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)15.2 %
Market Size (2024)USD 7,382.81 Million
Market Size (2031)USD 19,842.55 Million
Market ConcentrationLow
Report Pages303
7,382.81
2024
19,842.55
2031

Major Players

  • Edwards Lifesciences Corporation
  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • LivaNova PLC
  • JenaValve Technology, Inc
  • Meril Life Sciences Pvt. Ltd
  • Bracco Imaging S.p.A
  • CryoLife, Inc
  • Transcatheter Technologies GmbH

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market

Fragmented - Highly competitive market without dominant players


The TAVR/TAVI market is witnessing consistent growth, driven by a rising inclination toward minimally invasive cardiovascular procedures. This method offers reduced recovery times, lower surgical risks, and enhanced patient comfort compared to conventional surgeries. As healthcare systems adopt more patient-centric approaches, the demand for less invasive aortic valve replacement solutions has increased notably. Nearly 65% of eligible patients now opt for catheter-based valve therapies, marking a significant shift in treatment preferences.

Aging Population and Increased Aortic Stenosis Prevalence
A key factor influencing market dynamics is the growing population affected by aortic stenosis, particularly among older individuals. With over 50% of aortic valve disease cases reported in patients above the age of 70, the appeal of procedures like TAVR has amplified. The minimally invasive nature of TAVR makes it a viable option for high-risk surgical patients, contributing to its surging adoption across clinical settings focused on geriatric care.

Technological Advancements Enhancing Device Performance
Breakthroughs in device design and catheter technology are redefining the landscape of valve replacement therapies. Innovations such as next-generation valves and improved delivery systems have enhanced both the safety and success rates of procedures. Currently, around 40% of TAVR procedures incorporate advanced valve systems that offer better anatomical fit and reduce complications, indicating strong technological progress in this segment.

Market Outlook Backed by Clinical Success and Supportive Policies
With a growing body of clinical evidence supporting its safety and effectiveness, the TAVR/TAVI procedure continues to gain acceptance among both patients and professionals. Approximately 55% of heart centers now include TAVR in their core service offerings, supported by favorable reimbursement frameworks and policy incentives. This alignment of clinical performance, patient demand, and policy backing is expected to maintain a strong growth trajectory for the market.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Procedure
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Application
    4. Market Snapshot, By Region
  4. Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Cardiovascular Diseases
        2. Increasing Demand for Minimally Invasive Procedures
        3. Increasing geriatric population with cardiac conditions
      2. Restraints
        1. High Cost of Devices
        2. Lack of Skilled Professionals
        3. Stringent regulatory approval processes
      3. Opportunities
        1. Development of Novel Devices
        2. Growing Awareness Programs
        3. Integration with advanced imaging and navigation tools
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market, By Procedure, 2021 - 2031 (USD Million)
      1. Transfemoral Implantation
      2. Transapical Implantation
      3. Transaortic Implantation
    2. Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market, By Product Type, 2021 - 2031 (USD Million)
      1. Mechanical Heart Valves
      2. Tissue Heart Valves
      3. Transcatheter Heart Valves
    3. Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market, By Application, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Cardiac Catheterization Laboratory
      3. Ambulatory Surgical Centers (ASCs)
      4. Others
    4. Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Edwards Lifesciences Corporation
      2. Medtronic plc
      3. Abbott Laboratories
      4. Boston Scientific Corporation
      5. LivaNova PLC
      6. JenaValve Technology, Inc
      7. Meril Life Sciences Pvt. Ltd
      8. Bracco Imaging S.p.A
      9. CryoLife, Inc
      10. Transcatheter Technologies GmbH
  7. Analyst Views
  8. Future Outlook of the Market